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Fluid resuscitation in the critically ill is a hot topic. The current strategy of rapid and adequate resuscitation in shock
followed by conservative fluid administration is often difficult to achieve with standard crystalloid solutions.
Research into alternative intravenous fluids tailored to individual patient needs is required. In the previous issue of
Critical Care, Somasetia and colleagues compare the effects of hypertonic sodium lactate with the World Health
Organization-recommended strategy of Ringer’s lactate resuscitation in children with severe Dengue, a viral
infection for which causal treatment and vaccination are not available. The results not only suggest unimpaired
lactate metabolism during shock in children but document improvement in endothelial barrier function, limited
coagulopathy, and avoidance of fluid overload with hypertonic sodium lactate. Their study invites several important
questions to be answered. Is hypertonicity or lactate per se important for the beneficial effects? Are the metabolic
or anti-inflammatory effects responsible? Is the raised lactate in shock an adaptive response? Should reduction in
lactate levels be the goal of resuscitation? These questions may trigger further research into the role of lactate and
lactate-based intravenous fluids in resuscitation of the critically ill.Dengue fever is the most prevalent mosquito-borne viral
illness in humans. In tropical and subtropical countries,
an estimated 500,000 patients, mostly children, require
hospitalization each year, with overall mortality rate
around 2.5%, however reaching up to around 40% in cases
with established shock [1,2]. There are four serotypes of the
enveloped, single-stranded RNA Dengue virus. Immunity
following infection with one serotype does not protect the
host from being infected by another serotype and in fact
may trigger more severe disease [3,4].
The hallmarks of severe Dengue infection, also termed
Dengue hemorrhagic fever (DHF) and Dengue shock
syndrome (DSS), are mucosal bleeding and vascular
leakage syndrome due to complex interplay between the
virus, platelets, and immune and endothelial cell activation
leading to barrier dysfunction, plasma leakage, hemo-
concentration, thrombocytopenia, and coagulopathy [5].
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spiratory, cardiac, hepatic, and cerebral function impair-
ment [2]. The molecular events triggered by the virus
lead to endothelial activation with type I interferon
and pro-inflammatory cytokine production associated
with swelling of endothelial cells and shedding of ad-
hesion molecules such as vascular cell adhesion
molecule-1 (VCAM-1) [6]. Although it has been proposed
that soluble VCAM-1 (sVCAM-1) levels may reflect se-
verity of DHF/DSS, this remains unproven [7].
The World Health Organization (WHO) recommends
that patients with DHF/DSS be treated with an immediate
volume replacement using isotonic crystalloid solutions,
followed by the use of plasma or colloid solutions for
profound or continuing shock [2]. The goals of fluid re-
suscitation include decreasing tachycardia and improv-
ing pulse volume, capillary refill time, and end-organ
perfusion while correcting metabolic acidosis. During the
critical and recovery phase, however, excessive fluid therapy
is associated with pulmonary edema, congestive heart
failure, massive pleural effusion, and ascites. In this respect,
the study by Somasetia and colleagues in the previous
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WHO recommendation-based protocol of fluid resus-
citation with Ringer’s lactate (28 mmol/L) or to hypertonic
sodium lactate (HSL) solution that contains 504 mmol/L of
lactate. Apart from reaching their primary endpoint of re-
duction in sVCAM-1, suggesting reduced inflammatory ac-
tivation of the endothelium, the lactate-based regime was
associated with several important effects.
First, the volume of fluid required in the HSL group
was much lower during the 12-hour intervention period
to the extent that the overall fluid balance was neutral.
This may be related to the following: (a) HSL is a hyper-
tonic solution that may draw interstitial fluid back into
the vasculature; (b) lactate as a metabolizable anion may
lead to chloride egress from endothelial cells, causing
reduction in swelling and improved barrier function [8];
and (c) it was recently shown that lactate by itself has
important anti-inflammatory properties that may have re-
duced inflammatory response and endothelial activation [9].
Second, plasma lactate levels actually fell in the HSL
group despite a substantial amount of infused lactate.
This suggests that these critically ill children had unim-
paired lactate metabolism. Consequently, the high strong
ion difference of the HSL solution resulted in metabolic
alkalosis and hypokalemia, which were similar to HSL
effects reported in a study by our group [10].
Third, although more rescue starch boluses were given
in the observation period (second 12 hours), suggesting
that the effect of HSL is short-lived, less blood products
were required, implicating a reduction in coagulopathy. The
reason for this is unclear but may be related to less hemodi-
lution and higher pH associated with HSL infusion.
The study by Somasetia and colleagues was a pilot
study with sVCAM-1 as a primary surrogate outcome of
limited clinical importance [7]. Despite this, the authors
made a substantial contribution to the important field of
fluid resuscitation in sepsis, particularly in the pediatric
population. The Fluid Expansion as Supportive Therapy
(FEAST) study has already challenged the concept that
large-volume fluid resuscitation is beneficial in sepsis [11],
and this study suggests that by using HSL solution instead
of standard fluid therapy, a smaller volume is required,
and this could be associated with less coagulopathy while
providing useful energetic substrate for vital organs,
reduce inflammation, correct acidosis, and end up with
a reasonable fluid balance avoiding the ‘Michelin man’
effect (increased interstitial fluid accumulation and per-
ipheral edema). Although the FEAST trial concerned
fluid resuscitation in bacterial sepsis and malaria,
which have pathogeneses different from those of DHF,
endothelial cell dysfunction is common to all. So one
may agree with the authors: ‘from a theoretical point of
view, the optimal treatment should address both the cause
(endothelial dysfunction) and consequence (hypovolemia)’of increased vascular permeability [1]. This work thus may
prompt trials of hypertonic lactate resuscitation in sepsis
with the aim to restore vascular permeability. Nevertheless,
one needs to take into account the potentially deleterious
effects of lactate on immune function in sepsis [12].
Abbreviations
DHF: Dengue hemorrhagic fever; DSS: Dengue shock syndrome; FEAST: Fluid
Expansion as Supportive Therapy; HSL: hypertonic sodium lactate;
sVCAM-1: soluble vascular cell adhesion molecule-1; VCAM-1: vascular cell
adhesion molecule-1; WHO: World Health Organization.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MN drafted the commentary. All authors contributed intellectually to its
content and read, revised, and approved the final manuscript.
Author details
1Department of Intensive Care Medicine, Sydney Medical School - Nepean,
University of Sydney, Nepean Hospital, Derby Street, Penrith, NSW 2750,
Australia. 2Department of Pediatrics, Sydney Medical School - Nepean,
University of Sydney, Nepean Hospital, Derby Street, Penrith, NSW 2750,
Australia.
References
1. Somasetia DH, Setiati TE, Sjahrodji AM, Idjradinata PS, Setiabudi D, Roth H,
Ichai C, Fontaine E, Leverve XM: Early resuscitation of Dengue Shock
Syndrome in children with hyperosmolar sodium-lactate: a randomized
single blind clinical trial of efficacy and safety. Crit Care 2014, 18:466.
2. World Health Organization: Dengue: guidelines for diagnosis, treatment,
prevention and control (new edition 2009). [http://whqlibdoc.who.int/
publications/2009/9789241547871_eng.pdf]
3. Patkar C, Giaya K, Libraty DH: Dengue virus type 2 modulates endothelial
barrier function through CD73. Am J Trop Med Hyg 2013, 88:89–94.
4. Weiskopf D, Sette A: T-cell immunity to infection with dengue virus in
humans. Front Immunol 2014, 5:93.
5. Srikiatkhachorn A, Spiropoulou CF: Vascular events in viral hemorrhagic
fevers: a comparative study of dengue and hantaviruses. Cell Tissue Res
2014, 355:621–633.
6. Koraka P, Murgue B, Deparis X, Van Gorp EC, Setiati TE, Osterhaus AD, Groen J:
Elevation of soluble VCAM-1 plasma levels in children with acute
dengue virus infection of varying severity. J Med Virol 2004, 72:445–450.
7. Page AV, Liles CW: Biomarkers of endothelial activation/dysfunction in
infectious diseases. Virulence 2013, 4:507–516.
8. Hoffmann EK, Lambert IH, Pedersen SF: Physiology of cell volume
regulation in vertebrates. Physiol Rev 2009, 89:193–277.
9. Dietl K, Renner K, Dettmer K, Timischl B, Eberhart K, Dorn C, Hellerbrand C,
Kastenberger M, Kunz-Schughart LA, Oefner PJ, Andreesen R, Gottfried E,
Kreutz MP: Lactic acid and acidification inhibit TNF secretion and glycolysis
of human monocytes. J Immunol 2010, 184:1200–1209.
10. Nalos M, Leverve XM, Huang SJ, Weisbrodt L, Parkin R, Seppelt IM, Ting I,
Mclean AS: Half-molar sodium lactate infusion improves cardiac
performance in acute heart failure: a pilot randomized controlled clinical
trial. Crit Care 2014, 18:R48.
11. Maitland K, Kiguli S, Opoka RO, Engoru C, Olupot-Olupot P, Akech SO, Nyeko R,
Mtove G, Reyburn H, Lang T, Brent B, Evans JA, Tibenderana JK, Crawley J, Russell
EC, Levin M, Babiker AG, Gibb DM, FEAST Trial Group: Mortality after fluid bolus
in African children with severe infection. N Engl J Med 2011, 364:2483–2495.
12. Gottfried E, Kunz-Schughart LA, Ebner S, Mueller-Klieser W, Hoves S, Andreesen R,
Mackensen A, Kreutz M: Tumor-derived lactic acid modulates dendritic
cell activation and antigen expression. Blood 2006, 107:2013–2021.
doi:10.1186/s13054-014-0614-x
Cite this article as: Nalos et al.: Is lactate the new panacea for
endothelial dysfunction? Critical Care 2014 18:614.
